VIKING THERAPEUTICS INC (VKTX) Fundamental Analysis & Valuation
NASDAQ:VKTX • US92686J1060
Current stock price
32.985 USD
+0.23 (+0.72%)
At close:
33 USD
+0.02 (+0.05%)
After Hours:
This VKTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. VKTX Profitability Analysis
1.1 Basic Checks
- VKTX had negative earnings in the past year.
- In the past year VKTX has reported a negative cash flow from operations.
- VKTX had negative earnings in each of the past 5 years.
- VKTX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- VKTX has a Return On Assets (-50.25%) which is in line with its industry peers.
- VKTX has a Return On Equity (-56.28%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -50.25% | ||
| ROE | -56.28% | ||
| ROIC | N/A |
ROA(3y)-28.55%
ROA(5y)-30.53%
ROE(3y)-31.14%
ROE(5y)-33.61%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for VKTX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. VKTX Health Analysis
2.1 Basic Checks
- VKTX has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for VKTX has been increased compared to 5 years ago.
- VKTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- An Altman-Z score of 27.30 indicates that VKTX is not in any danger for bankruptcy at the moment.
- The Altman-Z score of VKTX (27.30) is better than 90.87% of its industry peers.
- VKTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 27.3 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- VKTX has a Current Ratio of 9.33. This indicates that VKTX is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Current ratio, with a value of 9.33, VKTX is in the better half of the industry, outperforming 78.06% of the companies in the same industry.
- A Quick Ratio of 9.33 indicates that VKTX has no problem at all paying its short term obligations.
- The Quick ratio of VKTX (9.33) is better than 78.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.33 | ||
| Quick Ratio | 9.33 |
3. VKTX Growth Analysis
3.1 Past
- The earnings per share for VKTX have decreased strongly by -218.00% in the last year.
EPS 1Y (TTM)-218%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-331.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- Based on estimates for the next years, VKTX will show a very strong growth in Earnings Per Share. The EPS will grow by 25.91% on average per year.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-37.93%
EPS Next 2Y-21.19%
EPS Next 3Y-10.9%
EPS Next 5Y25.91%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. VKTX Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for VKTX. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VKTX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A cheap valuation may be justified as VKTX's earnings are expected to decrease with -10.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-21.19%
EPS Next 3Y-10.9%
5. VKTX Dividend Analysis
5.1 Amount
- No dividends for VKTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
VKTX Fundamentals: All Metrics, Ratios and Statistics
32.985
+0.23 (+0.72%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-11 2026-02-11/amc
Earnings (Next)04-29 2026-04-29/amc
Inst Owners63.48%
Inst Owner Change0.17%
Ins Owners2.79%
Ins Owner Change1.57%
Market Cap3.82B
Revenue(TTM)N/A
Net Income(TTM)-359.64M
Analysts84.8
Price Target95.46 (189.4%)
Short Float %21.31%
Short Ratio8.8
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-34.26%
Min EPS beat(2)-51.32%
Max EPS beat(2)-17.21%
EPS beat(4)0
Avg EPS beat(4)-29.95%
Min EPS beat(4)-51.32%
Max EPS beat(4)-17.21%
EPS beat(8)3
Avg EPS beat(8)-10.43%
EPS beat(12)5
Avg EPS beat(12)-6.84%
EPS beat(16)6
Avg EPS beat(16)-5.84%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-0.5%
EPS NQ rev (1m)5.1%
EPS NQ rev (3m)-8.38%
EPS NY rev (1m)1.93%
EPS NY rev (3m)-15.5%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 5.98 | ||
| P/tB | 5.98 | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.18
EYN/A
EPS(NY)-4.39
Fwd EYN/A
FCF(TTM)-2.4
FCFYN/A
OCF(TTM)-2.4
OCFYN/A
SpS0
BVpS5.51
TBVpS5.51
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -50.25% | ||
| ROE | -56.28% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-28.55%
ROA(5y)-30.53%
ROE(3y)-31.14%
ROE(5y)-33.61%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 9.33 | ||
| Quick Ratio | 9.33 | ||
| Altman-Z | 27.3 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-218%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-331.25%
EPS Next Y-37.93%
EPS Next 2Y-21.19%
EPS Next 3Y-10.9%
EPS Next 5Y25.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-160.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-57.58%
EBIT Next 3Y-20.98%
EBIT Next 5Y17%
FCF growth 1Y-217.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-217.44%
OCF growth 3YN/A
OCF growth 5YN/A
VIKING THERAPEUTICS INC / VKTX Fundamental Analysis FAQ
What is the ChartMill fundamental rating of VIKING THERAPEUTICS INC (VKTX) stock?
ChartMill assigns a fundamental rating of 3 / 10 to VKTX.
What is the valuation status of VIKING THERAPEUTICS INC (VKTX) stock?
ChartMill assigns a valuation rating of 0 / 10 to VIKING THERAPEUTICS INC (VKTX). This can be considered as Overvalued.
How profitable is VIKING THERAPEUTICS INC (VKTX) stock?
VIKING THERAPEUTICS INC (VKTX) has a profitability rating of 1 / 10.
What is the financial health of VIKING THERAPEUTICS INC (VKTX) stock?
The financial health rating of VIKING THERAPEUTICS INC (VKTX) is 8 / 10.